< IP News

Spherix Stocks Soar after Executing Option Agreement for Coronavirus Patent

Shares of Spherix Inc. soared on 6 March 2020 shortly after the company announced that it had executed an exclusive option agreement with the University of Maryland, Baltimore, for the technology claimed in a patent entitled “Methods of Treating Coronavirus Infection”. The patent claims a method for treating coronavirus by administering a therapeutically effective amount of kinase signaling inhibitor selected from the group consisting of imatinib mesylate, nilotinib hydrochloride and dasatinib. It will be interesting to see if the method is effective for treating COVID-19.

Read more here.

Information made available on this website in any form is for information purposes only. It is not, and should not be taken as legal advice. You should not rely on, or take or fail to take any action, based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Oyen Wiggs Green & Mutala LLP professionals will be pleased to discuss resolutions to specific legal concerns you may have.